Not only has PTX-100 a great safety profile in terms of potential side effects but it also clears quickly from the system so drug-to-drug interactions are not an issue either. When treating older patients with more than one health condition which could involve umpteen different meds, oncology treatment for those patients must be a nightmare. So, Prof MP would be really keen to see PTX-100 get over the line and onto the market, for sure.
Ann: PTX-100 receives U.S. FDA Fast Track Designation, page-75
Add to My Watchlist
What is My Watchlist?
